Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer
SAN DIEGO — Treatment with raludotatug deruxtecan (R-DXd) led to an “exciting” response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to an early-phase trial. In a subgroup analysis of the first-in-human phase I study, there was one complete response and 17 partial responses among 37 evaluable patients treated with R-DXd, an […]